JamesRichardBerensonMD

PubMed

• The inhibitory receptor PVRIG is dominantly expressed in the bone marrow of patients with multiple myeloma and its blockade enhances T-cell engager's immune activation.
  Masha Frenkel, Zoya Alteber, Ning Xu, Mingjie Li, Haiming Chen
  Experimental Hematology. 2024-12-16
• Serum B-Cell Maturation Antigen Reflects Disease Status in a Patient Who Developed Nonsecretory Multiple Myeloma: A Case Report.
  Ryan Danis, Bernard Regidor, Sean Bujarski, Scott Jew, Marissa-Skye Goldwater
  Case Reports in Oncology. 2024-07-12
• A Phase I Trial Evaluating the Addition of Lenalidomide to Patients with Relapsed/Refractory Multiple Myeloma Progressing on Ruxolitinib and Methylprednisolone.
  James R Berenson, Andrea Limon, Stephanie Rice, Tahmineh Safaie, Ralph Boccia
  Targeted Oncology. 2024-05-01

Abstracts/Posters

• Comparative Analysis of sSLAMF7, sBCMA, and M-Protein As Prognostic, Predictive, and Pharmacodynamic Biomarkers in Relapsed/Refractory Multiple Myeloma Treated with Po...
  James R. Berenson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• The JAK1/2 Inhibitor Ruxolitinib Downregulates CXCL12 Secretion from Bone Marrow Stromal Cells and M2 Macrophage Polarization in Multiple Myeloma
  James R. Berenson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Ruxolitinib Reverses Checkpoint Inhibition By Downregulating PD-L1 and PD-L2 Expression on Both Tumor and Stromal Cells in Multiple Myeloma
  James R. Berenson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Normalization of Serum B-Cell Maturation Antigen Levels from Treatment Predicts Progression Free and Overall Survival in Multiple Myeloma Patients
  James R. Berenson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• The JAK1/2 Inhibitor Ruxolitinib Downregulates CXCL12 Secretion from Bone Marrow Stromal Cells and M2 Macrophage Polarization in Multiple Myeloma
  James R. Berenson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• A phase I trial of ruxolitinib, lenalidomide, and methylprednisolone for patients with relapsed/refractory multiple myeloma (MM). 
  2019 ASCO Annual Meeting - 6/1/2019
• A Phase 1 Trial of Ruxolitinib, Lenalidomide and Methylprednisolone for Relapsed/Refractory Multiple Myeloma Patients 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Baseline and Early Changes in Serum B-Cell Maturation Antigen Levels Predict Progression Free Survival and Response Status for Multiple Myeloma Patients in a Phase 1 T... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• The JAK Inhibitor Blocks PD-L1, PD-L2 and CD44 Expression in Multiple Myeloma (MM) and Sensitizes MM Cells to Lenalidomide and Steroids 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• A phase 1 trial of ruxolitinib, lenalidomide, and methylprednisolone for relapsed/refractory multiple myeloma patients. 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/1/2018
• Join now to see all

Other

• Treatment of hypercalcemia 
  Berenson JR, Shane E
  http://www.uptodate.com/contents/treatment-of-hypercalcemia
  UpToDate, Wolters Kluwer Health - 2012-09-12
• The use of bisphosphonates in patients with multiple myeloma 
  Berenson JR
  http://www.uptodate.com/contents/the-use-of-bisphosphonates-in-patients-with-multiple-myeloma
  UpToDate, Wolters Kluwer Health - 2012-06-29
• Risks of therapy with bone modifying agents in patients with advanced malignancy 
  Berenson JR, Stopeck AT
  http://www.uptodate.com/contents/risks-of-therapy-with-bone-modifying-agents-in-patients-with-advanc
  UpToDate, Wolters Kluwer Health - 2013-01-22